Leonie de Best on Validation of EMC92/SKY92 Signature in Myeloma

Leonie de Best, MSc2
Published: Wednesday, May 04, 2016



Leonie de Best, MSc2, chief operating officer, SkylineDX, discusses the HOVON-87/NMSG-18 study, which demonstrated the validation of the EMC92/SKY92 signature for elderly patients with newly diagnosed multiple myeloma. In the study, patients enrolled in the trial were stratified using the signature.

The HOVON-87/NMSG-18 study investigated patients who received induction therapy with melphalan, prednisone and thalidomide, followed by thalidomide maintenance therapy, compared with those who received melphalan, prednisone and lenalidomide, followed by lenalidomide maintenance therapy.

The EMC92/SKY92 signature was used in this study to identify patients with myeloma who are at high risk for poor prognosis and have a minimal progression-free survival rate, de Best explains. The EMC92/SKY92 signature was demonstrated to be a useful prognostic marker in the elderly population, she adds.




Leonie de Best, MSc2, chief operating officer, SkylineDX, discusses the HOVON-87/NMSG-18 study, which demonstrated the validation of the EMC92/SKY92 signature for elderly patients with newly diagnosed multiple myeloma. In the study, patients enrolled in the trial were stratified using the signature.

The HOVON-87/NMSG-18 study investigated patients who received induction therapy with melphalan, prednisone and thalidomide, followed by thalidomide maintenance therapy, compared with those who received melphalan, prednisone and lenalidomide, followed by lenalidomide maintenance therapy.

The EMC92/SKY92 signature was used in this study to identify patients with myeloma who are at high risk for poor prognosis and have a minimal progression-free survival rate, de Best explains. The EMC92/SKY92 signature was demonstrated to be a useful prognostic marker in the elderly population, she adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x